Lisata Therapeutics, Inc. (LSTA) Q3 2024 Earnings Call Transcript Summary
Lisata Therapeutics, Inc. (LSTA) Q3 2024 Earnings Call Transcript Summary
General and administrative expenses saw an increase of 8.1%, attributed to higher consulting expenses.The following is a summary of the Lisata Therapeutics, Inc. (LSTA) Q3 2024 Earnings Call Transcript:
以下是Lisata Therapeutics, Inc.（LSTA）2024年第三季度業績會記錄的摘要：
Financial Performance:
財務業績:
Lisata Therapeutics reported a decrease in operating expenses for Q3 2024, totaling $5.3 million compared to $6 million in the same period last year.
Research and development expenses decreased by 24.8%, largely due to reduced expenses in clinical research organization and lower equity expense associated with Phase IIa BOLSTER trial modifications.
General and administrative expenses saw an increase of 8.1%, attributed to higher consulting expenses.
Net losses improved to $4.9 million in Q3 2024 from $5.3 million in Q3 2023.
Lisata Therapeutics報告2024年第三季度營業費用減少，總計530萬美金，相較於去年同一時期的600萬美金。
研發費用減少了24.8%，主要由於臨床研究組織的費用降低以及與第二期BOLSTER試驗修改相關的股權費用減少。
一般和行政費用增加了8.1%，歸因於諮詢費用的增加。
淨虧損在2024年第三季度改善至490萬美金，相較於2023年第三季度的530萬美金。
Business Progress:
業務進展：
Lisata is advancing the development of certepetide across multiple solid tumors including pancreatic, cholangiocarcinoma, and others, with ongoing and planned clinical trials such as the ASCEND and BOLSTER trials.
Significant regulatory designations have been achieved, including orphan drug and Fast Track designations, enhancing the development pathway for certepetide.
The company has initiated preclinical investigations of certepetide for non-oncological uses, specifically in the treatment of endometriosis, indicating a strategic expansion of the therapeutic applications of certepetide.
Lisata正在推進certepetide在多種固體腫瘤中的開發，包括胰腺癌、膽管癌等，並進行正在進行和計劃中的臨床試驗，如ASCEND和BOLSTER試驗。
已經取得了重要的監管認定，包括孤兒藥和快速通道認定，增強了對certepetide的開發路徑。
公司已啓動對certepetide在非腫瘤用途方面的臨床前研究，特別是在治療子宮內膜異位症方面，這表明對certepetide治療應用的策略擴展。
Opportunities:
機會：
Lisata continues to explore strategic partnerships and expand its development strategy in both oncologic and non-oncologic fields, leveraging existing clinical and preclinical collaborations to maximize the therapeutic potential of certepetide.
Lisata繼續探索戰略合作伙伴關係，並擴大其在腫瘤和非腫瘤領域的發展策略，利用現有的臨床和臨床前合作，最大化certepetide的治療潛力。
Risks:
風險：
Slow initial enrollment rate in the GBM trial, particularly in Latvia, has posed challenges, despite optimization efforts. This might impact the timelines and expected outcomes of the trial.
儘管進行了優化努力，但在拉脫維亞，GBm試驗的初始招募速度緩慢，這帶來了挑戰。這可能會影響試驗的時間表和預期結果。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由人工智能生成。內容準確性無法完全保證。如需更全面詳情，請參閱IR網站。本文僅供投資者參考，不具有任何指導或推薦建議。
